American Association for Cancer Research
epi-23-0763_supplemental_table_s3_suppst3.docx (20.65 kB)

Supplemental Table S3 from Patient Willingness to Use a Pharmacy-Based Colorectal Cancer Screening Service: A National Survey of U.S. Adults

Download (20.65 kB)
journal contribution
posted on 2024-01-09, 08:21 authored by Parth D. Shah, Mary Wangen, Catherine L. Rohweder, Austin R. Waters, Olufeyisayo O. Odebunmi, Macary W. Marciniak, Renée M. Ferrari, Stephanie B. Wheeler, Alison T. Brenner

Conditions under which ambivalent or unwilling survey responders would be willing to participate in PharmFIT.


Centers for Disease Control and Prevention (CDC)

Safeway Foundation



We aimed to understand U.S. adults’ willingness to use a pharmacy-based fecal immunochemical test (FIT) distribution service for routine colorectal cancer screening called PharmFIT using Diffusion of Innovation Theory, evaluating patient's appraisals of the program's relative advantage, compatibility, and complexity. From March to April 2021, we conducted a national online survey of 1,045 U.S. adults ages 45 to 75. We identified correlates of patient willingness to use PharmFIT using structural equation modeling. Most respondents (72%) were willing to get a FIT from their pharmacy for their regular colorectal cancer screening. Respondents were more willing to participate in PharmFIT if they perceived higher relative advantage ($\hat{\beta}$= 0.184; confidence interval, CI95%: 0.055–0.325) and perceived higher compatibility ($\hat{\beta}$ = 0.422; CI95%: 0.253–0.599) to get screened in a pharmacy, had longer travel times to their primary health care provider ($\hat{\beta}$ = 0.007; CI95%: 0.004–0.010). Respondents were less willing to participate in PharmFIT if they were 65 years or older ($\hat{\beta}$ = −0.220; CI95%: −0.362 to −0.070). Most U.S. adults would be willing to participate in PharmFIT for their routine colorectal cancer screening. Patient perceptions of the relative advantage and compatibility of PharmFIT were strongly associated with their willingness to use PharmFIT. Pharmacies should account for patient preferences for these two traits of PharmFIT to increase adoption and use. Pharmacy-based colorectal cancer screening may be a viable public health strategy to significantly increase equitable access to screening for U.S. residents.

Usage metrics

    Cancer Epidemiology, Biomarkers & Prevention



    Ref. manager